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Accepted 10 December 2010AbstractObjective: To explore how patients’ treatment preferences were expressed and justified during recruitment to a randomized controlled
trial (RCT) and how they influenced participation and treatment decisions.
Study Design and Setting: Qualitative analysis of audio recordings of recruitment appointments with 93 participants aged 51e70 years
in a UK multicenter RCT of localized prostate cancer treatments.
Results: Treatment preferences at recruitment were more complex and dynamic than previously assumed. Most participants expressed
views about treatments early in appointments, ranging on a continuum from hesitant to well-formed opinions. As recruiters elicited men’s
views and provided detailed evidence-based treatment and study information, some opted for their preference, but many became uncertain
and open to RCT recruitment, often accepting a different treatment from their original ‘‘preference.’’ Discussion of treatment preferences
did not act as the expected barrier to recruitment but actively enabled many to express their concerns and reach an informed decision that
often included RCT participation.
Conclusion: Exploring treatment preferences and providing evidence-based information can improve levels of informed decision mak-
ing and facilitate RCT participation. Treatment preferences should be reconceptualized from a barrier to recruitment to an integral part of
the information exchange necessary for informed decision making about treatments and RCT participation.
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Randomized controlled trials (RCTs) are increasing in
number and complexity to tackle key evaluative health care
questions, but overcoming recruitment difficulties and in-
creasing participation rates are still a challenge [1]. Low
rates of recruitment may threaten the external validity of
RCTs [2], lead to the need for considerable further re-
sources, or cause trials to end prematurely, leaving impor-
tant research questions unanswered. Recruitment to RCTs
should only occur when there is ‘‘equipoise’’duncertainty
over the most effective treatment [3]dand when potential
recruits have been given sufficient information to make an
informed choice about participation [4]. Patients’ treatment
preferences have been identified as a barrier to trial recruit-
ment and one of the major reasons for low participation* Corresponding author. Tel.: þ44-117-928-7210; fax: þ44-117-928-
7292.
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Open access under CC BY license. levels [5e7]. A recent systematic review showed that sub-
stantial numbers of potential recruits refused randomization
because of treatment preferences, particularly those who
were employed and well educated [7].
Although the impact of patients’ treatment preferences
on RCT recruitment is thought to be considerable, research
to understand these preferences is meager and lacks theo-
retical insight [8]. The vast majority of studies that assessed
the impact of treatment preferences on randomized trials
identified through recent systematic reviews have assumed
that preferences were easily defined and measured [7,9].
‘‘Simple preferences’’ have been elicited ‘‘whereby the par-
ticipants indicated which treatment they preferred’’ [9,p. 5]
using ‘‘very simple measures’’ [10,p. iii] such as single-
item scales, with little consideration of validity, reliability,
or sensitivity [11], or what was being measured. However,
a small but significant body of literature emphasized the
complexity of treatment preferences, revealing them as
multifaceted psychological phenomena that could change
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 Patients’ treatment preferences expressed during
randomized controlled trial (RCT) recruitment
were found to be more complex and dynamic than
previously assumed in the literature, ranging on
a continuum from hesitant views to strong inten-
tions to receive a particular treatment.
 Exploration of treatment preferences by recruit-
ment staff facilitated recruitment by helping poten-
tial trial participants to express their concerns,
focus views, and reach an informed decision about
RCT participation or choice of treatment.
 Patients’ treatment preferences should be reconcep-
tualized from a ‘‘barrier’’ to trial recruitment to an
integral part of the information exchange necessary
for informed decision making about treatments and
trial participation.
 Future research should focus on developing strate-
gies to support trial recruiters in carefully eliciting
and exploring treatment preferences so that they
can provide targeted information to those who need
it most.
over time and required rigorous assessment in trials
[11e13]. Moreover, studies have shown that the way in
which information about different treatments in both clini-
cal practice and trials is presented to patients, for example,
positively or negatively framed survival probabilities and
verbal or numerical risks of disease recurrence, shapes their
attitude toward the treatments offered [14e18]. A recent
conceptual framework to understand patients’ treatment
preferences and their effects on decision making in RCTs
further highlighted the complex nature of preferences
[19]. The framework proposed the development of prefer-
ences within trials as a four-stage process relating to infor-
mation, reasoning, judgment, and decision making, each
stage with implications for recruitment procedures, but
the authors conceded that more theoretical and empirical
research were required to test its usefulness [19]. Little is
known empirically about how preferences are expressed
by patients during RCT appointments and whether these
can be addressed to improve the levels of recruitment.
We investigated how treatment preferences were
expressed and discussed with recruitment staff during
routinely audiotape-recorded recruitment appointments in
a multicenter RCT of treatments for localized prostate can-
cer (the ProtecT [Prostate cancer testing and Treatment]
study). These appointments were ‘‘real-life’’ interactions be-
tween recruiters and potential RCT participants and enabled
a detailed prospective investigation using qualitative re-
search methods of how preferences were initially expressedand justified, how they changed during recruitment dis-
cussions, and how they impacted on participation and treat-
ment decisions. Insights from these dynamic interactions
provided a framework for investigating the role of treatment
preferences in informed consent and RCT recruitment.2. Patients and methods
2.1. Study group
In the ProtecT study, overall 2,698 men aged 50e69
years and diagnosed with localized prostate cancer after
community-based prostate-specific antigen (PSA) testing
attended an appointment with a study nurse to consider
recruitment to an RCT comparing radical prostatectomy,
radical conformal radiotherapy, and active monitoring of
PSA levels (!1% of eligible men did not attend) (for fur-
ther details, see Ref. [20]). Before the appointment, men
were provided with a detailed written patient information
sheet containing details about treatments and the need for
an RCT. Recruiters were research nurses, predominantly
female, with many holding senior positions and having pre-
vious experience of research. Nurses were given training
and feedback to ensure that they provided accurate and
detailed information about the study and treatments and
to enable recruitment to be as uniform as possible across
the different centers. A checklist was provided to remind
them of the essential study information concerning diagno-
sis, advantages and disadvantages of treatments (including
those outside the trial), the need for an RCT, the purpose
of randomization, and the right to refuse participation or
take time to consider. They were encouraged to elicit
and explore potential participants’ preferences before
assisting them in reaching an informed decision about par-
ticipation or treatment [14,20]. If men expressed a clear
preference for one of the treatments or were not willing
to be randomized, nurses enabled them to select a treatment;
if they were sufficiently uncertain and willing to consider
all three treatments, they were invited to have their treat-
ment randomly allocated. The ProtecT study was designed
as a comprehensive cohort RCT [21]dall those diagnosed
with prostate cancer (randomized or not) were followed up
in the same way.
2.2. Data collection and analysis
Recruitment appointments in the ProtecT study were
routinely audiotape recorded for training and monitoring
purposes [22]. This enabled a systematic assessment of in-
teractions between participants and recruiters and, in this
analysis, particular focus on treatment preferences. All re-
cruitment appointments across all nine clinical centers over
a 3-month period (October to December 2005) were in-
cluded in this qualitative study. Men attended one appoint-
ment (with the exception of two men who attended two
appointments), lasting between 30 minutes and 2.5 hours,
Table 1
Study sample characteristics (n5 93)
Patient characteristics n %
Age at recruitment appointment (y)
50e54 5 5
55e59 15 16
60e64 38 41
65e70 35 38
Mean age (SD) 62 4.56
Ethnicity
White 91 98
Other 2 2
Marital status
Married/living as married 76 82
Single/widowed/divorced/separated 17 18
Socioeconomic statusa
Managerial and professional 33 37
Intermediate 14 16
Working 43 48
Grade of cancer (Gleason score)
6 (lower risk) 72 77
7/8b (higher risk) 21 23
Study center
A 9 10
B 9 10
C 7 8
D 6 6
E 17 18
F 16 17
G 9 10
H 11 12
I 9 10
Abbreviation: SD, standard deviation.
a Based on the UK National Statistics Socio-Economic Classification
(three-class version) [23]dthree missing observations.
b Only two participants had grade 8.
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across the sample was assessed in relation to routine study
data available on age, marital status, ethnicity, grade of
tumor (Gleason score), and center. Sociodemographic data
were obtained from questionnaires completed at the time of
PSA testing (ie, before diagnosis), and the UK National
Statistics Socio-Economic Classification system was used
to assign a socioeconomic group on the basis of their
occupational title and responsibilities [23]. The relation-
ship between preference categories and study center, soci-
odemographic data, and cancer staging was assessed using
chi-square, Fischer exact test, and t-test techniques in
Stata v11 (StataCorp LP, College Station, TX, USA).
N.M. initially listened to all recruitment appointments to
identify the initial expression and justification of treatment
preferences, which were then compared with the outcome
of the appointment. However, treatment preferences were
not expressed as simply as the systematic reviews had sug-
gested [7,9]. Although most men did express a view about
treatments early in appointments, most were hesitant about
their views and some did not express a preference at all.
The definition of a ‘‘treatment preference’’ was problematic
because there was variation in the way it was expressed be-
tween participants and over time. A more detailed formal
qualitative analysis was then undertaken by N.M. to inves-
tigate how the treatment views or preferences were ex-
pressed (in favor or against a treatment), when they were
uttered, how strongly they were held and justified, and what
happened to these views/preferences during discussion with
the recruiter. The relationships between the expressed
views/preferences and the decision to be randomized and
the treatment the participant finally agreed to were also ex-
plored. Analysis was an iterative processda repeated cycle
of coding and interpretation. Verbatim transcripts of re-
cruitment appointments were prepared, and data items were
systematically assigned codes using the qualitative data
organization package Atlas.ti V5 (Scientific Software De-
velopment GmbH, Berlin, Germany). At this point, a second
experienced social scientist (J.W.) analyzed 10 random re-
cruitment appointments (approximately 10% of the data)
independently to compare coding and enhance its reliabil-
ity. Areas of disagreement (few were major) were discussed
and resolved, and the coding framework was refined and re-
applied to the data. Similar codes were grouped to produce
categories or themes using content analysis techniques [24]
and methods of constant comparison [25]. Instances where
there was apparent contradiction between the initial treat-
ment preference and the outcome of the appointment were
identified separately as potential negative cases [26] and re-
analyzed in detail using audio and transcribed data to gain
a deeper understanding of the data and increase the trust-
worthiness of the findings. N.M. and J.L.D. met regularly
to review findings in detail and discuss theoretical develop-
ment. The findings are displayed as flow charts and in an-
alytic accounts below. Further quotations to support data
interpretation are in Appendix on the Web.3. Results
During the specified period, 108 recruitment appoint-
ments were conducted and 93 were recorded successfully.
The appointments were broadly representative of the Pro-
tecT study: they were conducted in all study centers and in-
cluded participants across the age range, in working class
and managerial/professional positions, with the commonest
grade of PSA-detected localized prostate cancer (Gleason
score 6), and married or living as married (Table 1). In
terms of the outcome of recruitment, they were also broadly
representative as 69 (74%) agreed to be randomized (60 of
whom accepted the allocated treatment) and 24 (26%) se-
lected their treatment [20]. The findings are presented be-
low in three sections. First, issues related to the difficulty
of defining simple treatment preferences are presented.
Second, the dynamic nature of the treatment views and
preferences is shown, including how they changed over
time and in response to interactions with recruiters. Finally,
treatment views and preferences are considered in relation
to the outcome of the appointmentsdwhether patients were
recruited to the RCT or chose a treatment.
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or a complex continuum?
Most participants (64 of 93 [69%]) expressed views about
treatments early in the appointments, based on information
gleaned from the study patient information sheet, lay sources,
general practitioners, or media/Internet (Appendix w1):ID 69: ‘‘I thought because you heal better as you’re
younger and fitter. if you’re going to have anything
major you’re best doing it while your body’s fit
enough. might as well get it all done now [surgery]
while I’m fit, because you never know with your
health do you.’’ (Study center F)Sometimes men expressed a view with clarity (Appendix
w2):ID 80: ‘‘Surgery rids the prostate and therefore rids
the cancer. I would be worried about it spreading if
I had active monitoring.’’ (Study center I)But other men expressed views more hesitantly
(Appendix w3):ID 63: ‘‘If I did have anything done, I would prefer the
surgery.. I don’t know thatmuch about it but I think if
you have surgery umm probably they could remove
something umm (pause) and I, I would sooner have that
then the uhh radiotherapy or the uhh monitoring be-
cause this is just my personal view.’’ (Study center D)Some expressed views that were not concordant with
scientific evidence:ID 35: ‘‘[Having surgery] puts cancer some place else
. [Radiotherapy] makes all your hair fall out.’’
(Study center I)Expressed preferences thus varied from relatively un-
formed views about treatments to clear requests for a treat-
ment. Each of the quotations above could be said to contain
a treatment ‘‘preference’’ddefined as an opinion about a po-
tential treatment option. However, many of the views con-
tained caveats or were limited by the lack of clarity from
the source of information, and so it would be difficult to claim
that any of these treatment ‘‘preferences’’ were fully in-
formed. Indeed, several men were explicit that they were ex-
pressing a view rather than a preference (see also ID 63
above):ID 26: ‘‘Active monitoring sounds to me like the right
thing to do. That’s what I feel at the moment. I’m
sure I could be talked out of it.’’ (Study center G)If recruiters had simply accepted these views as ‘‘prefer-
ences’’ without further exploration, this would likely have
resulted in these men choosing a treatment. However, ap-
pointments in this study were conducted within an RCT
in which recruiters were trained to listen to and acknowl-
edge these opinions, explain the reasons for the RCT, andpresent detailed information about each treatment to ensure
that a fully informed treatment or RCT participation deci-
sion was reached [20]. The recordings of the appointments
made it possible to investigate prospectively what happened
to treatment views expressed early on in response to infor-
mation provided by recruiters.
3.2. The development of ‘‘views’’ into treatment
preferences or uncertainty
As appointments proceeded, initial treatment views and
preferences were explored by participants and recruiters in
the context of the study information. Two clear groups
of participants from across all study centers then
emergeddthose who sustained or developed a clear treat-
ment preference and those who remained or became uncer-
tain (Fig. 1). There were no differences in terms of
sociodemographic characteristics or cancer staging between
the two groups with the exception of socioeconomic status:
men who sustained or developed a clear treatment preference
were more likely to be in managerial/professional occupa-
tional positions than those who remained or became uncer-
tain (11 of 15 [73%] vs. 17 of 47 [36%]; P5 0.02).3.2.1. Participants who sustained or developed a clear
treatment preference
There were 16 participants (25% of those expressing
views initially) whose views became focused into a clear
preference for one treatment:ID 01: ‘‘In my head you’ve now firmed everything
up. by electing to stay in the study I’m not in con-
trol. I’ve always been in control of everything and
that is why I wish to opt out of the study and go
for regular monitoring . I don’t think at this stage
I need [further information] cos I have made up my
mind. I’m quite happy that it’s monitoring.’’ (Study
center A; chose active monitoring in consultation)All 16 participants who expressed such a clear preference
obtained the treatment theywanted (Fig. 2). As can be seen in
Fig. 1, 13 patients chose their treatment outside the RCTand
3 were recruited. These three should probably not have been
randomized. Detailed examination of their appointments re-
vealed that they expressed their treatment preference clearly
but also insisted that they wanted to remain in the study and
contribute to it fully by being randomized. Twowere then al-
located, by chance, to their preferred treatment and accepted
it; the other declined the ‘‘wrong’’ allocation and chose his
preferred treatment. Ultimately, all these participants held
preferences strong enough to ensure that they received their
preferred treatment.
3.2.2. Participants who became uncertain
Most (48 [75%]) of those who had initially expressed
views about treatments became uncertain as recruiters
  )% 9 6 (   46 
y l l a i t i n i   de s s e r p x e   sw e i V 
) % 1 8 (   31 
  tn e m t a e r t   es o h C 
  fo   tr a t s   ta   st n a p i c i t r a p   39 
n o i t a t l u s n o c   tn e m t i u r c e r 
  )% 7 6 (   2
d e t p e c c A 
n o i t a c o l l a 
) % 9 8 (   43 
d e t p e c c A 
n o i t a c o l l a 
) % 1 1 (   4
d e n i l c e D 
n o i t a c o l l a 
) % 3 3 (   1
d e n i l c e D 
n o i t a c o l l a 
  )% 0 0 1 (   91 
d e t p e c c A 
n o i t a c o l l a 
) % 1 2 (   01 
  tn e m t a e r t   es o h C 
) % 1 3 (   92 
y l l a i t i n i   de s s e r p x e   sw e i v   oN 
  la i t i n i   es o h c   31 
e c n e r e f e r p 
  de n g i s s a   2
e c n e r e f e r p 
  de n g i s s a   to n   1
e c n e r e f e r p 
  la i t i n i   es o h c   2
; e c n e r e f e r p 
r e h t o   es o h c   8
  de n g i s s a   *4 1 
e c n e r e f e r p 
  de n g i s s a   to n   3
e c n e r e f e r p 
e s i o p i u q e   oN   /  ec n e r e f e r p   ra e l C e s i o p i u q E   /  ec n e r e f e r p   oN 
  fo   no i s s u c s i d   de l i a t e D 
e l a n o i t a r   la i r t   &  st n e m t a e r t 
  fo   no i s s u c s i d   de l i a t e D 
e l a n o i t a r   la i r t   &  st n e m t a e r t 
  )% 5 2 (   61 
  ec n e r e f e r p   ra e l C 
) % 6 6 (   91 
  ec n e r e f e r p   oN 
) % 0 1 (   1
  tn e m t a e r t   es o h C 
) % 4 4 (   4
d e n i l c e D 
n o i t a c o l l a 
) % 6 5 (   5
d e t p e c c A 
n o i t a c o l l a 
) % 9 1 (   3
  ot   de zi m o d n a R 
t n e m t a e r t 
) % 9 7 (   83 
  ot   de zi m o d n a R 
t n e m t a e r t 
) % 0 9 (   9
  ot   de zi m o d n a R 
t n e m t a e r t 
) % 0 0 1 (   91 
  ot   de zi m o d n a R 
t n e m t a e r t 
e c n e r e f e r p   es o h c   1
  de n g i s s a   to n   3
e c n e r e f e r p 
  de n g i s s a   3
e c n e r e f e r p 
) % 4 3 (   01 
  ec n e r e f e r p   ka e W 
  )% 5 7 (   84 
n i a t r e c n U 
d e g r e m e   ec n e r e f e r P n i a t r e c n U 
e c n e r e f e r p   la i t i n i   es o h c   1   ;e c n e r e f e r p   la i t i n i   es o h c   3
r e h t o   es o h c   1
  ;e c n e r e f e r p   es o h c   3
r e h t o   es o h c   1
Fig. 1. The development or dissipation of participants’ treatment preferences during (and in some cases after) the recruitment appointments. * indicates that
one man did not state what treatment his preference referred to.
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creasing uncertainty meant that participation in the RCT
became more acceptable [Appendix w4]:ID 52: ‘‘When I came in I thought I’ll get surgery and
have done with it . but I am listening to you and
now I’ve swung towards the radiotherapy . The
monitoring would be nice, um, but I just need some-
thing to be done . and I’m not happy to go through
an operation which, if the radiotherapy works, I
wouldn’t have had to have had . Well you’ve given
me another alternative to how I was thinking.’’
RECRUITER: ‘‘So you’re feeling more open to the
radiotherapy?’’
ID 52: ‘‘Yes yes.’’
RECRUITER: ‘‘And a little bit open to the active
monitoring?’’
ID 52: ‘‘Yes . well it’s reassured me ..’’
RECRUITER: ‘‘And a bit open to the surgery ..’’ID 52: ‘‘That’s right.’’ (Study center E; randomized to
radiotherapy, accepted allocation in consultation)As can be seen in the quotation above and Fig. 2, many of
these participants accepted treatment that differed from their
first expressed view/preference. Of the 48 who had ex-
pressed a view and then became uncertain, 38 (79%) agreed
to be randomized (Fig. 1), and of these, 34 accepted the al-
location. Scrutiny of the appointments of the four partici-
pants who refused the random allocation revealed evidence
of uncertainty in their appointments and willingness to con-
sider all three treatments at the point of randomization, but
when the allocation was given to them, they requested time
to reconsider. Three later rejected the allocation and opted
for their initially expressed view; the other chose a treatment
different from their original view. The process of being allo-
cated to a treatment appeared to help focus their minds on
which treatment they could really accept.
The remaining 10 men who became uncertain as the
appointment progressed decided to choose a treatment
(Fig. 1). Like other uncertain participants, their initial views
evolved after provision of further information by recruiters.
These participants were unwilling to accept randomization
as amethod to determine their treatment or expressed serious
) % 1 3 ( 9 2 
s w e i v o N 
y l l a i t i n i d e s s e r p x e 
f o s g n i d r o c e r h t i w n e m 3 9 
s t n e m t n i o p p a t n e m t i u r c e r 
) % 9 6 ( 4 6 
d e s s e r p x e s w e i V 
y l l a i t i n i 
) % 0 0 1 ( 6 1 
l a n i g i r o d e v i e c e R 
e c n e r e f e r p 
) % 0 ( 0 
r e h t o d e v i e c e R 
t n e m t a e r t 
* ) % 0 4 ( 9 1 
l a n i g i r o d e v i e c e R 
e c n e r e f e r p 
* ) % 8 5 ( 8 2 
r e h t o d e v i e c e R 
t n e m t a e r t 
) % 0 7 ( 7 
d e v i e c e R 
e c n e r e f e r p 
) % 0 3 ( 3 
r e h t o d e v i e c e R 
t n e m t a e r t 
) % 5 2 ( 6 1 
e c n e r e f e r p r a e l C 
) % 5 7 ( 8 4 
n i a t r e c n U 
) % 4 3 ( 0 1 
e c n e r e f e r p k a e W 
) % 6 6 ( 9 1 
e c n e r e f e r p o N 
Fig. 2. Participants’ treatment preferences in relation to outcome of trial recruitment. * indicates that one man did not state what treatment his preference
referred to.
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randomization was not a suitable option (Appendix w5).
Eight of these 10 chose a treatment different from their orig-
inally expressed view, evidence that treatment choice was
revised in response to information provision and that the
ultimate choice was, therefore, more informed.3.3. Relationships between treatment views/preferences
and recruitment outcome
Some relationships between early expressed treatment
views and the outcome of the appointments were relatively
straightforward, particularly at the extremes illustrated in
Fig. 1. There were, for example, 13 participants whose ini-
tial view was sustained and they chose their preferred treat-
ment; similarly, there were 19 who did not express a view
about treatments at all and then agreed to be randomized
and accepted the allocation (Fig. 1). In the latter group,
scrutiny of their appointments confirmed that they were
given detailed information by recruiters from the different
study centers and had had opportunities to ask questions,
but they appeared content with recruitment to the RCT
and did not express a treatment preference. These men were
less likely to hold managerial/professional occupational po-
sitions than the remaining men who expressed some kind of
preference (3 of 19 [16%] vs. 30 of 71 [42%]; P5 0.04),
but they did not differ with respect to other sociodemo-
graphic characteristics or cancer staging.
In most cases, the relationship between the early ex-
pressed treatment view and the ultimate outcome of the
appointment was not easily predictable or simple (Fig. 2).
Among the 48 who became uncertain during theappointments, for example, 19 received their originally ex-
pressed preference, but 28 accepted a different treatment
(Fig. 2). Randomization appeared to help when an early
preference was replaced by uncertainty:RECRUITER: ‘‘If you’ve got an absolute fixed sense
of what you want to do then we won’t bother with
randomisation ..’’
ID 06: ‘‘I think I’ll, I would like to have it eradicated and
go for radiotherapy.That’s justmy feelings at themoment
. with the monitoring it’s still there, I’d like to get rid
of it. [Discussion about active monitoring].. The
good thing I suppose with active monitoring you know
one or two years down the line it’s still the same, so it
can be the same in the next couple of years..’’
RECRUITER: ‘‘.. You say that you’re sort of fo-
cused on the radiotherapy, but it sounds to me that,
I can see in some ways that each of these [treatments]
appeal on different levels.’’
ID 06: ‘‘That’s right yeah.’’
RECRUITER: ‘‘So you would be able to think about
all of these?’’
ID 06: ‘‘Yeah that’s right.’’
RECRUITER: ‘‘So therefore perhaps let’s see what
comes up with the randomisation and you can then
make a decision, accept or not?’’
1133N. Mills et al. / Journal of Clinical Epidemiology 64 (2011) 1127e1136ID 06: ‘‘Yeah, yeah.’’ (Study center H; randomized to
surgery, accepted after consultation)In the above excerpt, the recruiter could have considered
that the initially expressed ‘‘preference’’ for radiotherapy
should have precluded participation in the RCT. However,
further discussion discovered uncertainty and meant that re-
cruitment became a reasonable option. Randomization then
helped this man (and others) to focus their views on the
acceptability of a particular treatment.
There was a further group of 10 participants across five
different study centers who did not express a view origi-
nally and then became rather indecisive, expressing
a mix of uncertainty and rather weak noncommittal views
(Fig. 1). Most (nine) agreed to randomization, but they
split almost equally in terms of whether they accepted/
rejected the allocation and whether they received the
treatment they seemed to prefer (Fig. 1). Detailed scrutiny
of these appointments suggested that these participants
had considerable difficulty deciding on participation or
treatment:ID 81: ‘‘I would prefer to be monitored but the other
two [treatments] don’t frighten me in any way.’’
RECRUITER: ‘‘No, so you’ve got no strong objec-
tions to any of them?’’
ID 81: ‘‘No, no strong . no, well the treatments
don’t bother me, it’s all this time off work.’’
[Discussion about time off work]
RECRUITER: ‘‘The next step is entirely up to you
what to do.’’
ID 81: ‘‘Hmm, see then [do the randomization].’’
(Study center A; randomized to radiotherapy, de-
clined, chose active monitoring after consultation)In this example, it might be considered that the partici-
pant should not have been randomized. However, the
expression of the ‘‘preference’’ is not much different from
the previous example in which the allocation was accepted.
In the appointment, the recruiter has to make a judgment
without the benefit of this detailed examination and hind-
sight. Moreover, these participants seemed to need random-
ization and then time after the appointment to consider
whether they could accept the allocated treatment.4. Discussion
This study has shown that treatment preferences ex-
pressed by potential RCT participants vary along a contin-
uum from hesitant opinions to well-formed intentions toreceive a particular treatment and that in many cases, these
‘‘preferences’’ can change after detailed discussion of treat-
ments and trial rationale with recruitment staff. It seems
likely from systematic reviews [5,7,9] and low rates of re-
cruitment of eligible participants into RCTs [1] that many
of these initial treatment views have been taken on face
value to be ‘‘simple treatment preferences’’ and led directly
to treatment. However, the prospective nature of this re-
search has shown that these views were far from simple
or static and that when these views were elicited and dis-
cussed, there was only a weak relationship between partic-
ipants’ initial views and the treatments finally received.
Only a small minority of participants did not express treat-
ment views, seemingly content to accept recruitment to the
RCT. The vast majority did express their views and dis-
cussed them willingly with recruiters trained to explore
their preferences in the context of available evidence.
During these interactions, the quarter with strong views jus-
tified them and went on to receive their preferred treatment.
The other three-quarters became uncertain, and after further
discussions with recruiters, most agreed to be recruited to
the RCT, often eventually accepting a treatment different
from their originally expressed ‘‘preference.’’ The process
of preference exploration, and in some cases randomization
itself, appeared to help to formulate informed decisions.
These findings raise a number of issues about the inter-
pretation of the current literature concerned with treatment
preferences. Many of these studies, including several sig-
nificant systematic reviews [5,7,9], failed even to provide
a definition of preferences because they were considered
simple in conceptual and measurement terms. Where
a definition was provided, such as ‘‘a greater liking for
one alternative over another,’’ [27] this failed to encapsulate
the range in strength and complexity, and dynamism, of
treatment preferences demonstrated in this study. This lack
of adequate definition of preferences may explain the lack
of progress so far noted in this field [8]. There is now
greater credence to the small number of studies that have
critiqued this research and attempted to investigate the
complexity of treatment preferences [11e13,19].
Previous studies have shown that treatment preferences
have an impact on RCT recruitment [5e7]. This study ex-
tends and clarifies this by showing that it is not just the ex-
istence of a preference that is important but the type and
strength of it and how it is then dealt with by recruitment
staff. In a systematic review of musculoskeletal RCTs,
57% of participants were considered to have expressed
a treatment preference [9]. This is similar to the 69% ex-
pressing initial treatment views in this study. However, in
this study, only one-quarter of those with these early
‘‘views’’ clearly upheld them and received their preferred
treatment. If such initial, rather ephemeral ‘‘likes/dislikes’’
early in the process of recruitment are accepted to be
treatment preferences, then large numbers of potential
participants will be excluded from RCT recruitmentd
effectively half the participants in this study. As many trials
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tion of the methods of preference exploration used in this
study could potentially considerably increase recruitment.
There is a balance to be struck in exploring treatment
preferences. If strongly held, informed preferences are eli-
cited from potential recruits, modern ethical standards [4]
mean that they should not be asked to consent to random-
ization but should receive their treatment of choice. Explor-
ing the origin and basis of such preferences has been
suggested to be potentially coercive [28]. There is consider-
able evidence in this study that participants were not co-
erced. For example, those whose views were strengthened
during the interactions all obtained their preferred treat-
ment, even when randomly allocated to a treatment they
did not favor. Likewise, for those who became uncertain af-
ter expressing an initial view or were uncertain at the start,
the process of recruitment and/or randomization helped
to focus their views into decisions. Exploration of initial
views about treatments in this study showed that some were
based on a misunderstanding of scientific evidence. Uncrit-
ical acceptance by recruiters of initial views essentially ex-
cludes potential participants from provision of full and
accurate treatment informationdand this, in turn, could
be seen to be unethical [14].
In the current literature, there is also interest in the effect
that patients’ treatment preferences can have on trial out-
come based on the theory that those with preferences
who consent to randomization may comply better and have
better outcomes if they are allocated to their preferred op-
tion [29] or suffer ‘‘resentful demoralization’’ with lower
motivation and poorer outcome if allocated to another treat-
ment [30]. The ‘‘fully randomized preference trial,’’ in
which participants’ preferences recorded before randomiza-
tion are taken into account in the analysis, attempts to mea-
sure such effects (see, eg, Refs. [31e33]). However, any
effect on outcome from such studies will depend on what
sort of ‘‘preferences’’ are measured, and as potential RCT
participants expressing a clear treatment wish should not
be randomized, this exposes a paradox. If preferences are
so weak that it is ethical for patients to be randomized, it
becomes difficult to imagine how such ephemeral views
could have an impact on outcomes such as symptoms or
quality of life. Research on treatment preferences in the
context of outcome will need to be reconceptualized in light
of these study findings.
This study has some limitations. It was set within a single
RCTwhere training had been provided to encourage discus-
sion of treatment preferences. This is a limitation in terms
of generalizability, but it enabled the key issues of the def-
inition of ‘‘preferences’’ and their complexity and dyna-
mism to be uncovered, and these aspects are likely to be
of relevance to other RCTs. The study was unusual in ana-
lyzing routinely audiotape-recorded appointments rather
than participant and recruiter interviews. This limited the
study as it was not possible to pursue more about partici-
pants’ preferences and reflections on their definition ininterviews, but it did avoid reliance on post facto rational-
izations that have seriously limited interview-based studies
in this area [34]. The use of routinely recorded appoint-
ments also enabled a systematic and prospective qualitative
analysis of a relatively large number of recruitment ap-
pointments across nine centers and so was able to provide
insights, uniquely, from real-life appointments observed
as they happened.
Several methods were used to enhance the reliability and
trustworthiness of the data, including the iterative process
of going back and forth between coding and interpretation
as analysis proceeded, the use of the computer package At-
las.ti to help elicit and categorize findings in an exploratory
and systematic way, the active search for negative cases,
analyzing both audio and transcribed verbatim data for each
case, regular discussions of coding and emerging findings
within the research team, and extensive presentation of
raw data from different informants so readers can judge
the interpretation of data. The consistency of the findings
across centers suggests that the styles of individual re-
cruiters were not particularly influential, but in the study,
it must be remembered that recruiters were trained together.
The finding that men in managerial employment were more
likely than those with other occupations to have a clear
treatment preference was consistent with other research
[7,35].
Findings from this study may be applicable more widely
than recruitment to RCTs. The process of shared treatment
decision making in routine clinical practice involves a bal-
anced consideration of patients’ treatment preferences and
information/evidence provided by clinicians. In areas of
clinical practice, perhaps particularly where there is uncer-
tainty, awareness of the continuum on which patients’ pref-
erences might lie might enable clinicians to elicit and better
understand patients’ views so they can inform them of treat-
ment options in a more targeted way.
Future research, directed first to RCT recruitment, needs
to focus on developing interventions to improve RCT re-
cruitment and informed consent, within the context of dy-
namic treatment preferences and their role in treatment
decision making. It is possible to develop training sessions
to encourage recruiters to explore patients’ treatment pref-
erences so information can be tailored, which may, in turn,
result in more cost-effective RCT recruitment and more in-
formed decision making [20]. Findings from this study sug-
gest that the group of patients who may benefit the most
from exploration of preferences are those who express
a desire for a treatment early in the consultation but reveal
hesitancy or uncertainty as detailed treatment and trial
rationale information is given. Recent research has revealed
effective communication techniques used by trained re-
cruiters, for example, open questions, long pauses, and
readily ceding the floor, that have facilitated detailed and
systematic exploration of potential trial participants’ con-
cerns and understandings [14]. The key for future research
is to develop strategies to support recruiters in carefully
1135N. Mills et al. / Journal of Clinical Epidemiology 64 (2011) 1127e1136eliciting and exploring treatment preferences, building on
the techniques described above, so that they can identify
the more robust preferences from the ephemeral views
and provide targeted information to those who need it most.5. Conclusion
This study has provided detailed empirical evidence to
show that potential RCT participants’ treatment preferences
range on a continuum from ephemeral likes/dislikes to a de-
termination to receive a particular treatment. Preferences are
dynamic and can change after detailed discussion of treat-
ments and trial rationale with the recruitment staff. The
impact of potential participants’ treatment preferences on
recruitment needs to be reconsidered not as a ‘‘barrier’’ to re-
cruitment but as an integral part of the information exchange
necessary for informed decision making about treatments
andRCT participation. The evidence presented here suggests
that exploring patients’ views and preferences about treat-
ments and targeted information provision could lead to im-
proved levels of informed consent and RCT participation.Acknowledgments
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